title: [The therapeutic effects of basic fibroblast growth factor injected into tympanic cavity on sensorineural deafness].
abstract: OBJECTIVE
  To evaluate the therapeutic effects of basic fibroblast factor (bFGF) ototopically injected into tympanic cavity on sensorineural deafness.
  
  
  METHODS
  40 cases (50 ears) suffering from sensorineural deafness have been treated with bFGF,which was injected into tympanic cavity from 1998 to 1999. The hearing threshold of post-therapy was compaired with that of pre-therapy.
  
  
  RESULTS
  The total therapeutic effective rate of bFGF on the deafness was 96%. The hearing threshold of post-therapy was much lower than that of pre-therapy in average.
  
  
  CONCLUSIONS
  The bFGF could improve the hearing of sensorineural deafness patients. The method of ototopically injecting bFGF to tympanic cavity was safe and applicable.
authors.affiliation: Research Center of Basic and Clinic Medicine of Jiangsu University, Zhenjiang 212001.
authors.forename: Zhijian
authors.initials: Z
authors.lastname: Zhang
authors.forename: Yijuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Yi
authors.initials: Y
authors.lastname: Dou
authors.forename: Gaocan
authors.initials: G
authors.lastname: Sun
authors.forename: Qiusheng
authors.initials: Q
authors.lastname: Huang
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Guo
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D001301:Audiometry, Pure-Tone; D002648:Child; D004432:Ear, Middle; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D016222:Fibroblast Growth Factor 2